Designing vial systems to meet the demands of complex biologics
Large molecule medicines are transforming treatment paradigms for many chronic and debilitating diseases, targeting previously “undruggable” pathways and marking a…
Partner Content
-
-
Choosing a drug development partner in 2026: A practical selection framework
For emerging and mid-sized biopharma companies, selecting a drug development partner is now a strategic decision that can determine whether…
-
Peptide drug conjugates: How the Indena and Chemi partnership is delivering
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to…
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to…
-
Maximising data capture in obesity trials
Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines.…
-
Radiopharma on the rise: Are supply chains ready?
Radiopharmaceutical therapies are moving from niche innovation to a mainstream oncology option. For supply chains built around stable, mass-produced medicines,…
-
The future role of automation and AI in environmental monitoring
In pharmaceutical manufacturing, robust environmental monitoring is crucial for maintaining product quality and regulatory compliance. Historically, these practices have been…
-
How price variation impacts employers
This is the first episode in our second season exploring the evolving landscape of real-world data and its role in…
-
Q&A: How 3PLs are navigating the latest pharma trends
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
-
Accelerate post-approval research by streamlining the entire study lifecycle
As oncology therapies mature, post-approval research is essential to supporting regulatory commitments, label expansion, and real-world adoption—often under tight timelines.…